A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

The targeting of eosinophilic inflammation is a well-recognized strategy for the treatment of EGPA. 4,5,11 A previous clinical trial showed that treatment of EGPA with mepolizumab, a monoclonal ...

The phase 3 MATINEE trial (NCT04133909) provided additional context for where mepolizumab may be most useful. 2 This trial randomized 804 patients with a history of frequent exacerbations and ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England ...

Mepolizumab is the only approved biologic evaluated in patients with an eosinophilic phenotype characterized by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. 1,2 BEC is ...

Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial.

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD regardless of the history or severity of ...

Mepolizumab, sold as Nucala, was not compared fairly against other asthma treatments, raising questions as to whether it has benefits over other drugs already used for the condition, ...

Mepolizumab is currently being investigated for severe hypereosinophilic syndrome, nasal polyposis and COPD. In the US, Nucala (100mg fixed dose subcutaneous injection of mepolizumab ...

Mepolizumab (), an interleukin-5 antagonist, is currently approved for use as an add-on maintenance treatment for patients with severe asthma with an eosinophilic phenotype.It is also indicated in ...